Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73376 | 0.88 | L3MBTL1 (0.47) | L3MBTL1KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL73600 | 0.86 | L3MBTL1 (0.47) | L3MBTL1KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5640436 | 0.84 | KDM4E (0.42) | L3MBTL1KDM4EALDH1A1HPGDRPS6KB2 | |
| SCHEMBL15016169 | 0.79 | MTNR1A (0.47) | KDM4ECYP1A2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL1470493 | 0.76 | SMN1; SMN2 (0.58) | — | |
| SCHEMBL14564348 | 0.75 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10RPS6KB2 | |
| SCHEMBL72871 | 0.75 | KMT2A (0.47) | KDM4ECYP1A2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL73404 | 0.75 | TAAR1 (0.53) | — | |
| SCHEMBL5447789 | 0.73 | KDM4E (0.40) | KDM4EALDH1A1HPGDHSD17B10RPS6KB2 | |
| SCHEMBL468013 | 0.73 | MEN1 (0.58) | L3MBTL1TDP1ALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1620086-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION | Warner-Lambert Company LLC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6875780-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| WO-2004091604-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | BRATTON LARRY D (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARG, PPARD | L3MBTL1 4411/4885KDM4E 2473/4885CYP1A2 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.